Children with an incurable disease that causes rapid aging and early death may live longer if treated with an experimental drug first developed for cancer patients. Treatment with the drug, lonafarnib, was associated with a significantly lower mortality rate (3.7% vs 33.3%) over an ~2 year period.

The experimental drug may help patients live longer, new research suggests

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →